Newsletter Archive

  1. 04.27.16 -- Do Biosimilar Policies Alienate Physicians?
    4/27/2016

    04/27/16 BioProcess Online Newsletter

  2. 04.25.16 -- FDA Environments: Applying Human Performance Models
    4/25/2016

    04/25/16 BioProcess Online Newsletter

  3. 4.21.2016 -- Best Practices For Drug Delivery Device Development
    4/21/2016

    4.21.2016 -- Best Practices For Drug Delivery Device Development

  4. 04.20.16 -- How To Avoid Data Integrity And Quality Pitfalls
    4/20/2016

    04/20/16 BioProcess Online Newsletter

  5. 04.18.16 -- 4 Questions From The PDA Annual Meeting
    4/18/2016

    04/18/16 BioProcess Online Newsletter

  6. 04.13.16 -- Data Integrity: Understand Regulations And Enforcement Actions
    4/13/2016

    04/13/16 BioProcess Online Newsletter

  7. 04.11.16 -- Do FDA Biosimilar Regulations Defeat Purpose Of BPCIA?
    4/11/2016

    04/11/16 BioProcess Online Newsletter

  8. 04.06.16 -- What FDA's Biosimilar Workload Says About U.S. Market
    4/6/2016

    04/06/16 BioProcess Online Newsletter

  9. 04.04.16 -- Reformulation Impact On Biologics
    4/4/2016

    04/04/16 BioProcess Online Newsletter

  10. 03.30.16 -- 4 Key Trends In Biopharm Manufacturing
    3/30/2016

    03/30/16 BioProcess Online Newsletter